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Editors’ NotesRegulating Regeneration
Pluripotent cells hold great promise for regenerative medicine, and
model organisms such as the planarian—a flatworm that can regen-
erateanybodypart—offer insight into thepathwayscontrolling regen-
erative potential. In this issue, Reddien and colleagues use transcrip-
tional profiling to identify genesexpressed inplanarianstemcells, and
find both novel genetic regulators of stem cell biology and genes
conserved in stem cell populations in other organisms. Therapeutic
use of pluripotent cells, and particularly iPSCs, has come into ques-
tion recently with the identification of genomic instability in reprog-
rammed lines. However, using whole-genome sequencing of three
human iPSC lines derived froma single donor, Cheng and colleagues
now provide evidence that the reprogramming process is not inher-
ently mutagenic, although there is still a need to screen for endoge-
nous genetic variation. Cell-based therapies do not always need to
involve direct cellular replacement, and in their review article Karp
and colleagues highlight the growing interest in harnessing the broad
array of regulatory molecules secreted by mesenchymal stem cells
(MSCs) to reduce tissue damage in heart disease. At a broader level,
the therapeutic potential of such studies and many others is made
clear inaprofileonAFIRM, theArmedForces InstituteofRegenerative
Medicine, a5-year-old fundingprogramthat is focusedondeveloping
regenerative therapies that could be used to treat injured soldiers.Population Dynamics
Many stem cell populations contain a heterogeneous mix of cell subtypes with differences in self-renewal capacity and lineage
potential; two papers in this issue illustrate such complex hierarchical populations. Eaves and colleagues examine hematopoietic
stem cells (HSCs) in fetal and adult mice and present a timeline
of HSC expansion and differentiation throughout the life of the
mouse, in which the proportional representation of different
HSC subtypes within the overall pool shifts during the course
of the developmental program. Scadden and colleagues look
at MSCs and their derivatives in the bone marrow. More specif-
ically, they characterize osteoblastic cells and find that these
cells are short-lived and replenished by MSC-like cells.
However, while these MSC-like cells meet definitions of being
MSCs in vitro, they are restricted to the osteolineage in vivo
(see preview by Zaidi). These results suggest that MSCs in the
bone marrow are a heterogeneous population with a subset of
cells serving to replenish the skeleton.Expressing Control
Identifying an overarching signaling network that balances the regulation of cell fate decisions would offer far-reaching insight into plurip-
otent cell behavior as well as early embryonic development. In this issue, Dalton and colleagues put forth a model for such a signaling
framework,whereinPI3K/AktactivationofActivinA/Smad2,3 inducesprorenewal targetgenes,while in theabsenceofPI3K/Aktsignaling,
Wnt effectors act in conjunction with Smad2,3 to promote differentiation (see preview by Wang). Many of the transcription factors that
regulate embryonic tissue formation are still present in adult stem cells, but whether they perform the same function there is unclear.
Here, Pandolfi and colleagues show that Sall4, which is required for embryonic tissue development, takes on a distinct role in the differ-Celentiation of postnatal spermatogonial cells by phys-
ically interacting with Plzf, a transcription factor
required for adult stem cell maintenance. Also in
this issue, Rando and colleagues show that miR-
206 modulates expression of Pax3, a myogenic
regulator that is transientlyexpressed inadultmuscle
stem cells and a subset of quiescent stem cells
(QSCs). The variable expression of Pax3 appears
to be due to alternative polyadenylation of the Pax3
transcript in some QSCs, highlighting a mechanism
for evadingmiRNA regulation thatmayapply in other
stem cell contexts aswell (see previewby Rudnicki).l Stem Cell 10, March 2, 2012 ª2012 Elsevier Inc. ix
